PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer
Status:
Withdrawn
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety of PD-1 knockout engineered T cells in treating
metastatic advanced bladder cancer. Blood samples will also be collected for research
purposes.